Novo Nordisk's Rybelsus, the first oral GLP-1 in type 2 diabetes, is back on solid ground after the pandemic, and now looking to the future in obesity. (Credit: Shutterstock)
How Novo Nordisk’s Rybelsus went from pandemic washout to blockbuster, and what’s next for oral weight loss
Novo Nordisk’s Rybelsus pill was long expected to be a hit out of the gate.
The Danish drugmaker cashed in a priority review voucher in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
